# JNJ Stock Targeted for 15.57% Upside

> JNJ stock could rise 15.57% to $291.60 by 2030, with analysts bullish despite recent quarterly miss.
- Title: JNJ Stock Targeted for 15.57% Upside · 24/7 Wall St.
- Summary: JNJ stock could rise 15.57% to $291.60 by 2030, with analysts bullish despite recent quarterly miss. JNJ stock targets $291.60 in 12 months with 15.57%…
- Keywords: jnj, stock, price target, dividend, oncology, medtech, merck, abbvie, Targeted, Upside, 24/7 Wall St.
- Source: 24/7 Wall St. — https://247wallst.com/investing/2026/10/19/johnson-johnson-stock-could-be-a-defensive-play-for-the-years-ahead
- Author: Vandita Jadeja
- Published: 2026-10-19T11:15:21+00:00
- Read time: 1 min
- Topics: jnj, stock, price target, dividend, oncology, medtech, merck, abbvie
## JNJ Quarterly Results
JNJ reported third-quarter results with 6% sales growth to $25.4 billion and adjusted EPS of $2.59.
## Price Target Analysis
24/7 Wall St. targets $291.60 for JNJ stock, representing 15.57% upside from current price of $252.32.
## Dividend Strength
JNJ offers 1.99% dividend yield and 64 consecutive years of dividend increases.
## Oncology Growth
Oncology business growing at double-digit pace with TREMFYA up 68.2% and potential $10 billion franchise.
## MedTech Performance
MedTech grew 2.5% in Q3 but shares fell after device sales miss.
## Analyst Ratings
16 analysts rate JNJ a Buy or Strong Buy with 90% confidence in target.
## Key takeaway

JNJ stock targets $291.60 in 12 months with 15.57% upside from current price of $252.32.